Profound Medical Q2 Revenue Jumps 62% YTD, Losses Narrow as Commercialization Gains Traction

summarizeSummary

Profound Medical reported Q2 2026 revenue of $2.48 million, up 12% year-over-year, and a net loss of $9.54 million, a 39% improvement. First-half revenue surged 62% to $7.82 million, with operating expenses declining 13%.

check_boxKey Events · Earnings and Guidance · PROF

• Revenue Growth Accelerates

  Q2 2026 revenue rose 12% YoY to $2.48M; first-half revenue surged 62% to $7.82M, driven by higher capital equipment sales in the U.S. and overseas.

• Losses Narrow Sharply

  Net loss improved to $9.54M in Q2 2026 from $15.70M a year ago, a 39% reduction. First-half net loss was $16.59M vs. $26.42M in 2025.

• Operating Leverage Emerges

  Total operating expenses fell 16% in Q2 to $13.01M, with SG&A down 21% and R&D down 7%, while gross profit rose 20% to $1.95M.

• Cash Runway Confirmed

  Cash and equivalents stood at $38.27M as of June 30, 2026, down from $59.72M at year-end 2025. Management expects existing cash and product sales to fund operations for at least 12 months.

auto_awesomeAnalysis · PROF · Industrial Applications And Services

Profound Medical's second-quarter results show accelerating commercial momentum. Revenue more than doubled in the first half of 2026 compared to last year, driven by strong capital equipment sales in the U.S. and overseas. The company is also spending less to generate that growth — operating expenses fell 16% in the quarter — which helped cut the net loss nearly in half. Cash burn remains a concern, with reserves down to $38 million from $60 million at year-end, but management says the current runway is sufficient for at least another year. The numbers suggest the TULSA-PRO system is gaining real-world adoption, and the improving margin profile puts the company on a clearer path to breakeven.